ERBB2 and cancer: In conclusion, based on a large cohort of cancer patients, our study analyzed mutations in β3‐αC loop in kinase domain of EGFR, ERBB2, MAP2K1, and BRAF, and summarized the drug‐relevant mutations of each gene.